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Dyslipidemia has long been associated with b cell dysfunction in the development of diabetes. Tang et al.
(2015) have now revealed that b cell short-chain fatty acid receptors FFA2 and FFA3 are activated in an auto-
crine fashion and reduce insulin secretion in type 2 diabetes models.b cell dysfunction is the underlying cause
of type 2 diabetes (T2D), characterized
by insufficient insulin secretion to meet
metabolic demands. Elevated glucose
and fatty acids (FAs) have been associ-
ated with b cell failure through glucolipo-
toxicity (Poitout and Robertson, 2008);
however, the particular FAs mediating
this process remain unknown. In vitro
studies primarily use palmitic and oleic
acid to mimic in vivo dyslipidemia, though
the true lipid fingerprint of diabetes
is much more complex. Recent work
has confirmed that various metabolites
elevated in diabetes play a contributing
role in the development of b cell dysfunc-
tion (Newgard et al., 2009; Prentice et al.,
2014; Wang et al., 2013), highlighting the
complexity of this disorder. However, the
source of these metabolites is largely
thought to be from over-worked meta-
bolic tissues, including liver, muscle,
and adipose. In an intriguing recent article
in Nature Medicine, Tang et al. (2015)
have uncovered a role for short-chain
FAs (SCFAs) produced by b cells in regu-
lating glucose-stimulated insulin secre-
tion (GSIS) through the SCFA receptors
FFA2 and FFA3.
The G protein-coupled receptors
(GPCRs) FFA2 and FFA3 have been impli-
cated as mediators of glucose tolerance
because of their coupling to Gi proteins,
which act to inhibit cAMP accumulation
upon activation (Kebede et al., 2009). As
cAMP accumulation is essential for GSIS,
and particularly for incretin-stimulated
GSIS, this made FFA2 and FFA3 prime
targets to examine for a role in b cell dys-
function in T2D. Due to strong similarities
in expression profile and function between
the genes, loss of individual receptors
is likely compensated for by the other,
leading the researchers to adapt a dou-
ble-knockdown/out strategy to examine
the role of these receptors in GSIS.Tang et al. (2015) began by confirming
co-expression of FFA2 and FFA3 in
mouse and human primary b cells, and b
cell lines. Functionality of these receptors
was tested using the addition of the
endogenous agonist acetate, which
actively inhibited GLP-1-induced insulin
secretion in a dose-dependent manner.
Pre-treatment of the cells with the Gi
inhibitor pertussis toxin, or knockdown
of FFA2 and FFA3, blocked this effect,
establishing FFA2 and FFA3 as inhibi-
tors of insulin secretion. Importantly,
accumulation of endogenously produced
acetate, a SCFA produced through
glycolysis, recapitulated this effect in b
cells, suggesting autocrine inhibition of
insulin secretion through FFA2 and FFA3
(Figure 1).
To determine the role of FFA2 and FFA3
in glucose tolerance, Tang et al. (2015)
generated mice globally lacking FFA2
and FFA3. Mice were phenotypically
normal, with no difference in basal meta-
bolic rate or energy expenditure under
either normal chow or high-fat diet (HFD)-
fed conditions. However, while no differ-
ence was observed in the glucose toler-
ance of FFA2 and FFA3 knockout mice
under normal chow conditions, they ex-
hibited a robust improvement in their
glucose tolerance when challenged with
HFD. The phenotype was replicated in a
b cell-specific model of FFA2 and FFA3
deletion, indicating specificity of this ef-
fect in the b cell. Improved glucose toler-
ance correlated with enhanced plasma
insulin concentrations, and decreased
non-esterified FFA levels, consistent with
increased insulin activity, though no
change in insulin sensitivity. This suggests
that the role of FFA2 and FFA3 in regu-
lating insulin secretion is more prominent
under diet-induced obese and diabetic
conditions. Consistent with this obser-
vation, mice fed a HFD and humans withCell Metabolismdiabetes have increased circulating levels
of acetate that correspond to increased
expression of FFA2 and FFA3 in the islets
of HFD mice.
GLP1 plays a prominent role in potenti-
ating GSIS, a function that is preserved
in the islets of diabetic patients, making
incretin agonists excellent therapeutics
for T2D (Drucker, 2011). Enteroendocrine
cells express both FFA2 and FFA3, and
SCFAs are produced in large quantities
through the breakdown of dietary fiber
by the gut microbiome (Kebede et al.,
2009). Thus, the authors investigated
whether the effect on insulin secretion
in vivo is mediated by altered incretin
hormone release. Intestinal cell-specific
deletion of FFA2 and FFA3 had no effect
on insulin secretion, as mice challenged
with a systemic bolus of acetate had
no change in circulating insulin levels,
compared to a dramatic drop in plasma
insulin in b cell-specific FFA2 and FFA3
knockout mice. No difference in response
to oral glucose challenge in the intestinal-
specific knockouts was observed, sug-
gesting that the effect of FFA2 and FFA3
on mediating insulin secretion is inherent
to the b cell.
As fewer than half of overweight and
obese subjects develop diabetes in spite
of dyslipidemia, ectopic fat accumula-
tion, and massive insulin resistance, an
inherent b cell dysfunction makes sense.
Could these proteins represent novel ther-
apeutic targets to enhance insulin secre-
tion? Further investigation is warranted
to determine the underlying mechanism
of action of FFA2 and FFA3 in islets. While
Gi-coupled GPCRs inhibit cAMP accu-
mulation, they are also associated with
increasing multiple factors known to stim-
ulate GSIS from b cells (Kebede et al.,
2009; Le Poul et al., 2003). Furthermore,
the effect of FFA2 and FFA3 deletion in
isolated islets remains to be established.21, March 3, 2015 ª2015 Elsevier Inc. 353
Figure 1. Local and Systemic Acetate Activates FFA2 and FFA3 on
the Pancreatic b Cell to Impair Insulin Secretion under Diabetic
Conditions
Glucose is metabolized via glycolysis to increase production of short-chain
fatty acids (SCFAs), including acetate. Acetate accumulates locally and sys-
temically where it acts as an endogenous ligand for the SCFA receptors
FFA2 and FFA3. FFA2 and FFA3 are Gi-type G protein-coupled receptors,
which act to impair cAMP formation when activated, resulting in impaired
insulin secretion. Mice lacking FFA2 and FFA3 globally, or specifically in the
b cell, have enhanced insulin secretion and improved glucose tolerance
when challenged with the HFD.
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PreviewsAcetate preferentially accu-
mulates in the hypothalamus
and directly regulates appe-
tite through alterations in
metabolism (Frost et al.,
2014). Thus, effects of hypo-
thalamic deletion of FFA2
and FFA3 in both the whole
body and b cell-specific
knockoutmice couldmediate
the observed improvements
in glucose tolerance, as the
rat insulin promoter (RIP)
driving Cre may be active in
these regions of the brain.
Elevated circulating SCFAs
in HFD-fed mice and diabetic
humans implies an alternate
source of SCFAs to induce
b cell dysfunction, in addition
to an autocrine effect. The
role of the gut microbiome
in generating SCFAs may
come into play. While evi-
dence exists to suggest that
microbially produced SCFAs
are protective against insulin
resistance and glucose intol-
erance (Kimura et al., 2013),
their effects may differ be-
tween b cells and insulin-sen-sitive tissues where FFA2 and FFA3
are also expressed. This represents an
interesting avenue for future research.
The article by Tang et al. (2015) iden-
tifies the SCFA receptors FFA2 and
FFA3 as being expressed on b cells, and354 Cell Metabolism 21, March 3, 2015 ª201acting as important negative regulators
of insulin secretion when stimulated by
endogenous ligands, including acetate.
Thus, FFA2 and FFA3 are novel potential
therapeutic targets to specifically improve
b cell dysfunction in T2D.5 Elsevier Inc.REFERENCES
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